Arkolith/Insider Trading/AKTS/Form 4

Herrmann Ken

DirectorAktis Oncology, Inc. (AKTS) · full profile →Form 4 · filed Jul 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$77K
Net Open-Market Flow
-$77K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 17, 2026Option exercise(M)3K$0.08$2453K
Jul 17, 2026Sell(S)3K$25.21$77K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 17, 2026Option exercise(M)3K—$04K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-309115) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML